Prosecution Insights
Last updated: October 04, 2026

Qianjiang Yongan Pharmaceutical Co. Ltd.

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Qianjiang Yongan Pharmaceutical Co. Ltd. is managing 2 pending office actions within the Chemistry & Materials technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the company's current patent applications are being evaluated by different individuals in separate administrative groups, which may lead to different prosecution timelines and requirements for each matter.

The busiest examiner for the portfolio is KUYKENDALL, ALYSSA LEE, who is currently handling 1 busiest examiner pending action. With a total of 2 pending office actions, the workload is split between the 2 distinct examiners. The involvement of 2 distinct art units indicates that the company's technology is being classified into different specialized categories at the patent office. Practitioners should be prepared for the distinct procedural nuances that come with working across 2 distinct art units and 2 distinct examiners.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (50%)
0
Easy (0%)
1
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only1 (50%)
No statute on record1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KUYKENDALL, ALYSSA LEE 1 20.8% +95.0%
DOLETSKI, BLAINE G 1 75.0% +9.1%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18109074 SYSTEM FOR SYSTEM FOR PREPARING HIGH-PURITY TAURINE AND SALT KUYKENDALL, ALYSSA LEE 79d overdue

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18109074 SYSTEM FOR SYSTEM FOR PREPARING HIGH-PURITY TAURINE AND SALT KUYKENDALL, ALYSSA LEE 79d overdue

Top Art Units

Art UnitApps
1774 1
1692 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18109074 SYSTEM FOR SYSTEM FOR PREPARING HIGH-PURITY TAURINE AND SALT KUYKENDALL, ALYSSA LEE 1774 §103 Non-Final OA 79d overdue Pending Feb 13, 2023
18146472 HIGH-EFFICIENCY CYCLIC PREPARATION METHOD FOR COLUMNAR TAURINE DOLETSKI, BLAINE G 1692 — Final Rejection 26d Pending Dec 27, 2022

Managing Qianjiang Yongan Pharmaceutical Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month